Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Up 5.08%
As of Monday, July 27, Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 5.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Commentary & Analysis
Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Down 5.08%
As of Friday, July 24, Eupraxia Pharmaceuticals Inc.’s EPRX share price has dipped by 5.08%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Up 5.03%
As of Friday, July 17, Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 5.03%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Up 6.55%
As of Wednesday, June 17, Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 6.55%, which has investors questioning if this is right time to sell.Michael Rose
Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Down 8.36%
As of Tuesday, June 16, Eupraxia Pharmaceuticals Inc.’s EPRX share price has dipped by 8.36%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | EPRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $438.4 | $273.0 | 35% |
|
| Shares Out (Mil) | 66.2 | 53.1 | 54% |
|
| Institutional Ownership | 69.8% | 92.4% | 43% |
|
| Float (Mil) | 51.3 | 40.1 | 47% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 222 | 496 | 45% |
|
| Price Change (52-week) |
23.3% | 57.5% | 64% |
|
| Growth | EPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (65.6%) | (10.0%) | 4% |
|
| EPS (5yr) | (14.9%) | 16.0% | 18 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.7% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 10 | |
| Current EPS | ($0.251) | ($0.946) | ($1.013) | |
| Month Ago EPS | ($0.244) | ($0.975) | ($0.898) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.259) | ($1.059) | ($0.870) | |
| Year/Year Chg | 9.1% | (8.1%) | 15.1% | |
| Financials | EPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($50) | ($43) | 16% |
|
| EPS (TTM) | ($0.975) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $33 | $2 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $335 | $166 | 32% |
|
| Valuation | EPRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.34 | 2.71 | 74% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | EPRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (61.4%) | (47.7%) | 9% |
|
| ROE | (108.4%) | (55.1%) | 9% |
|
| Liabilities to Assets | 7.3% | 29.8% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Eupraxia Pharmaceuticals Inc. did not pass any screens on 8/14/2026.
